Naklofen Duo (Diclofenac Sodium)

Diclofenac sodium blocks the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for prostaglandin synthesis. By lowering prostaglandin levels, the drug reduces inflammation, pain signaling, and fever, providing the therapeutic effects typical of nonsteroidal anti‑inflammatory agents.

The specific dose of Naklofen Duo is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Healthcare professionals set the appropriate regimen and adjust it as needed.

Diclofenac sodium is generally avoided in the third trimester of pregnancy because of potential fetal cardiovascular effects. Use during pregnancy or lactation should only occur if the prescriber judges the benefit outweighs the risk, and it is typically discouraged unless no safer alternative exists.

To request Naklofen Duo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both diclofenac (Naklofen Duo) and ibuprofen belong to the NSAID class and share similar mechanisms of COX inhibition. Diclofenac often provides longer‑lasting analgesia and may be preferred for certain musculoskeletal conditions, while ibuprofen has a shorter half‑life and a slightly different safety profile, especially regarding gastrointestinal tolerance.

Naklofen Duo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Naklofen Duo is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with meals may reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe liver injury, and renal impairment. Patients should be monitored for signs of these conditions, especially if they have pre‑existing risk factors or are using the drug long‑term.

Individuals with known hypersensitivity to diclofenac or other NSAIDs, patients with active gastrointestinal ulcer disease, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment should avoid Naklofen Duo unless a specialist determines that benefits outweigh the risks.